Abstract
Specific sites of lysine methylation on histones correlate with either activation or repression of transcription1,2,3. The tumour suppressor p53 (refs 4–7) is one of only a few non-histone proteins known to be regulated by lysine methylation8. Here we report a lysine methyltransferase, Smyd2, that methylates a previously unidentified site, Lys 370, in p53. This methylation site, in contrast to the known site Lys 372, is repressing to p53-mediated transcriptional regulation. Smyd2 helps to maintain low concentrations of promoter-associated p53. We show that reducing Smyd2 concentrations by short interfering RNA enhances p53-mediated apoptosis. We find that Set9-mediated methylation of Lys 372 inhibits Smyd2-mediated methylation of Lys 370, providing regulatory cross-talk between post-translational modifications. In addition, we show that the inhibitory effect of Lys 372 methylation on Lys 370 methylation is caused, in part, by blocking the interaction between p53 and Smyd2. Thus, similar to histones, p53 is subject to both activating and repressing lysine methylation. Our results also predict that Smyd2 may function as a putative oncogene by methylating p53 and repressing its tumour suppressive function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zhang, Y. & Reinberg, D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 15, 2343–2360 (2001)
Lachner, M., O’Sullivan, R. J. & Jenuwein, T. An epigenetic road map for histone lysine methylation. J. Cell Sci. 116, 2117–2124 (2003)
Schotta, G. et al. A silencing pathway to induce H3–K9 and H4–K20 trimethylation at constitutive heterochromatin. Genes Dev. 18, 1251–1262 (2004)
Olivier, M., Hussain, S. P., Caron de Fromentel, C., Hainaut, P. & Harris, C. C. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci. Publ. 157, 247–270 (2004)
Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000)
Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 (1997)
Prives, C. & Hall, P. A. The p53 pathway. J. Pathol. 187, 112–126 (1999)
Chuikov, S. et al. Regulation of p53 activity through lysine methylation. Nature 432, 353–360 (2004)
Vaziri, H. & Benchimol, S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8, 279–282 (1998)
Luo, J. et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107, 137–148 (2001)
Wysocka, J., Myers, M. P., Laherty, C. D., Eisenman, R. N. & Herr, W. Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3–K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1. Genes Dev. 17, 896–911 (2003)
Rea, S. et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593–599 (2000)
Nishioka, K. et al. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev. 16, 479–489 (2002)
Kent, J. R. et al. During lytic infection herpes simplex virus type 1 is associated with histones bearing modifications that correlate with active transcription. J. Virol. 78, 10178–10186 (2004)
Brown, M. A., Sims, R. J., Gottlieb, P. D. & Tucker, P. W. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer 5, 26 (2006)
Acknowledgements
We thank N. Barlev for the Set9 expression vector and D. Reinberg for the p53K372me1 antibody; T. Waibel for assistance in cloning Smyd2; S. Benchimol for the BJ and BJ-DNp53 cell lines; and members of the T.J. and S.L.B. laboratories for discussions. Research in the laboratory of T.J. is supported by the IMP through Boehringer Ingelheim and by grants from the European Union and the Austrian GEN-AU initiative, which is financed by the Austrian Ministry of Education, Science and Culture. Research support to S.L.B. was provided by a grant from the NIH. B.J.P. was supported by a Wistar Cancer Training Grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests.
Supplementary information
Supplementary Notes
This file contains Supplementary Methods and Supplementary Figure Legends. (DOC 38 kb)
Supplementary Figures
This file contains Supplementary Figures 1–11. (PDF 505 kb)
Rights and permissions
About this article
Cite this article
Huang, J., Perez-Burgos, L., Placek, B. et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 444, 629–632 (2006). https://doi.org/10.1038/nature05287
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature05287
This article is cited by
-
Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide
Oncogene (2024)
-
Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data
Journal of Genetic Engineering and Biotechnology (2023)
-
Protein post-translational modifications in the regulation of cancer hallmarks
Cancer Gene Therapy (2023)
-
Lysine methyltransferase SMYD2 inhibits antiviral innate immunity by promoting IRF3 dephosphorylation
Cell Death & Disease (2023)
-
Tumor-suppressive functions of protein lysine methyltransferases
Experimental & Molecular Medicine (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.